Similarly, in two independent cohorts of NSCLC patients treated with a single-agent PD-(L)1 inhibitor, baseline corticosteroid treatment was associated with decreased overall response rate, progression-free survival, and overall survival [79]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.